Hong Soon-Cheol

Prof. Dr. Hong Soon-Cheol

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Lipid and Atherosclerosis
Verified
Journal Article
Open access
EREun-Jung Rhee
Eun-Jung Rhee
HKHyeon Chang Kim
Hyeon Chang Kim
JKJae Hyeon Kim
Jae Hyeon Kim
ELEun Young Lee
Eun Young Lee
BKByung Jin Kim
Byung Jin Kim
OAOn behalf of the Committee of Clinical Practice Guideline of Korean Society of Lipid and Atherosclerosis
On behalf of the Committee of Clinical Practice Guideline of Korean Society of Lipid and Atherosclerosis

1 September 2017 in Peptides
Verified
Journal Article
Closed access
YLYeji Lee
Yeji Lee
CPChanvorleak Phat
Chanvorleak Phat
HSHong Soon-Cheol
Hong Soon-Cheol

19 May 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MKMin Woo Kim
Min Woo Kim
KAKi Hoon Ahn
Ki Hoon Ahn
KRKi-Jin Ryu
Ki-Jin Ryu
HSHong Soon-Cheol
Hong Soon-Cheol
JLJi Sung Lee
Ji Sung Lee
HKHai-Joong Kim
Hai-Joong Kim
Although there is accumulating evidence regarding the additional protective effect of folic acid against adverse pregnancy outcomes other than neural tube defects, these effects have not been elucidated in detail. We evaluated whether folic acid supplementation is associated with favorable maternal and fetal outcomes. This was a secondary analysis of 215 pregnant women who were enrolled in our prior study. With additional data from telephone interviews regarding prenatal folic acid supplementation, existing demographic, maternal and fetal data were statistically analyzed. The concentration of folic acid in maternal blood was significantly higher following folic acid supplementation (24.6 ng/mL vs.11.8 ng/mL). In contrast, homocysteine level in maternal blood decreased with folic acid supplementation (5.5 µmol/mL vs. 6.8 µmol/mL). The rates of both preeclampsia (odds ratio [OR], 0.27; 95% confidence interval [CI], 0.09–0.76) and small for gestational age (SGA; 9.2% vs. 20.0%; OR, 0.42; 95% CI, 0.18–0.99) were lower in the folic acid supplementation group than those in the control group. Other pregnancy outcomes had no association with folic acid supplementation. The findings indicate that folic acid supplementation may help to prevent preeclampsia and SGA. Further studies are warranted to elucidate the favorable effects of folic acid supplementation on pregnancy outcomes.

Verified
Journal Article
Open access
PDF file
HSHye-Rim Seong
Hye-Rim Seong
CNChan Ho Noh
Chan Ho Noh
SPSangryong Park
Sangryong Park
SCSumin Cho
Sumin Cho
SHSeok-Jin Hong
Seok-Jin Hong
Yun-Bae KimYun-Bae Kim
Yun-Bae Kim
Glaucoma is one of the most devastating eye diseases, since the disease can develop into blindness and no effective therapeutics are available. Although the exact mechanisms and causes of glaucoma are unknown, increased intraocular pressure (IOP) has been demonstrated to be an important risk factor. Exosomes are lipid nanoparticles secreted from functional cells, including stem cells, and have been found to contain diverse functional molecules that control body function, inhibit inflammation, protect and regenerate cells, and restore damaged tissues. In the present study, exosome-rich conditioned media (ERCMs) were attained via hypoxic culture (2% O2) of human amniotic membrane mesenchymal stem cells (AMMSCs) and amniotic membrane epithelial stem cells (AMESCs) containing 50 times more exosome particles than normoxic culture (20% O2) medium (NCM). The exosome particles in ERCM were confirmed to be 77 nm in mean size and contain much greater amounts of growth factors (GFs) and neurotrophic factors (NFs) than those in NCM. The glaucoma-therapeutic effects of ERCMs were assessed in retinal cells and a hypertonic (1.8 M) saline-induced high-IOP animal model. CM-DiI-labeled AMMSC exosomes were found to readily penetrate the normal and H2O2-damaged retinal ganglion cells (RGCs), and AMMSC-ERCM not only facilitated retinal pigment epithelial cell (RPEC) proliferation but also protected against H2O2- and hypoxia-induced RPEC insults. The IOP of rats challenged with 1.8 M saline increased twice the normal IOP (12–17 mmHg) in a week. However, intravitreal injection of AMMSC-ERCM or AMESC-ERCM (3.9–4.5 × 108 exosomes in 10 μL/eye) markedly recovered the IOP to normal level in 2 weeks, similar to the effect achieved with platelet-derived growth factor-AB (PDGF-AB, 1.5 μg), a reference material. In addition, AMMSC-ERCM, AMESC-ERCM, and PDGF-AB significantly reversed the shrinkage of retinal layers, preserved RGCs, and prevented neural injury in the glaucoma eyes. It was confirmed that stem cell ERCMs containing large numbers of functional molecules such as GFs and NFs improved glaucoma by protecting retinal cells against oxidative and hypoxic injuries in vitro and by recovering IOP and retinal degeneration in vivo. Therefore, it is suggested that stem cell ERCMs could be a promising candidate for the therapy of glaucoma.

17 July 2006 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
HSHong Soon-Cheol
Hong Soon-Cheol
JSJae Yun Song
Jae Yun Song
JLJae Kwan Lee
Jae Kwan Lee
NLNak Woo Lee
Nak Woo Lee
SKSun Haeng Kim
Sun Haeng Kim
KLKyu Wan Lee
Kyu Wan Lee

1 January 2014 in Obstetrics & Gynecology Science
Verified
Journal Article
Open access
PDF file
ELEun Ju Lee
Eun Ju Lee
KAKi Hoon Ahn
Ki Hoon Ahn
HSHong Soon-Cheol
Hong Soon-Cheol
ELEun Hee Lee
Eun Hee Lee
YPYong Park
Yong Park
BKByung Soo Kim
Byung Soo Kim
Lymphoma, especially non-Hodgkin's lymphoma is extremely rare in pregnancy. A 24-year-old pregnant woman was diagnosed with diffuse large B-cell lymphoma (DLBCL), a subgroup of non-Hodgkin's lymphoma, at 24 weeks' gestation, and was treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy. After 4 cycles of R-CHOP, she delivered a healthy baby via cesarean section at 34 weeks and 5 days' gestation because of preterm contraction-related fetal distress. The patient was administered the remaining 2 cycles of R-CHOP after delivery. Follow-up magnetic resonance imaging and computed tomography showed complete remission. Here, we report a rare case of DLBCL successfully treated with R-CHOP chemotherapy during pregnancy, we also performed a systematic review of literature for similar cases. There were 3 earlier reports of R-CHOP treatment for DLBCL. All cases, including our case, resulted in preterm birth. Together, these findings suggest that R-CHOP chemotherapy for DLBCL in pregnancy may be associated with preterm birth.